Ed,
100 by year-end seems very aggressive to me, don't you think?. On the other hand, SEPR is entering that sweet sixteen time of a biotech's life, where tangible results are close at hand yet still not real, so our fantasies seem realizable and as yet have no blemishes. So maybe SEPR will have a huge run in here. Agouron did, before they started selling anything, and the stock has never returned to those old highs. Biogen also did very well before bringing their blockbuster to market, then spent most of '97 languishing as everybody wrung their hands worrying about patents, competition, side effects, what's in the pipeline. Of course, the pipeline at least is no worry for SEPR.
Anyway, my head's still spinning from 50!
Bruce
|
